Refractory antibody-mediated rejection after high-emergency lung transplantation for dermatomyositis with anti-MDA5 antibody:a case report
- Author:
Louise CHANTELOT
1
;
Domitille MOUREN
;
Jean-Luc TAUPIN
;
Aurélie CAZES
;
Jonathan MESSIKA
;
Cendrine GODET
;
Mathilde SALPIN
;
Gaelle WEISENBURGER
;
Brice LORTAT-JACOB
;
Pierre MORDANT
;
Jean-François ALEXANDRA
;
Raphael BORIE
;
Chloé COMARMOND
;
Yves ALLENBACH
;
Yurdagül UZUNHAN
;
Hervé MAL
;
Antoine ROUX
;
Vincent BUNEL
Author Information
- Publication Type:Case Report
- From: Clinical Transplantation and Research 2025;39(4):378-383
- CountryRepublic of Korea
- Language:English
- Abstract: This case report describes a female with amyopathic anti-MDA5+ dermatomyositis who underwent emergency double lung transplantation due to rapidly progressive interstitial lung disease. Following transplantation, she developed acute antibody-mediated rejection (AMR). Despite multiple rounds of immunosuppressive therapy, her condition continued to deteriorate, and her donor-specific anti-human leukocyte antigen antibody levels increased markedly. An experimental treatment, imlifidase—an immunoglobulin G endopeptidase—was employed as a rescue therapy. This case highlights the complexity of posttransplant management of AMR and emphasizes the need for dedicated clinical trials to provide additional data.
